Furthermore, targeting of EPHA10, EPHB4, ephrin-A2, and ephrin-A4, as well as ephrin-B2 in BC cells or xenograft models was associated with tumor regression, anticancer T-cell activation, and impaired cell motility. The gene discussed is EFNA2; the disease is neoplasm.